End-stage renal disease in patients with Fabry disease: Natural history data from the Fabry Registry

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 769-775

  Ortiz, Alberto ^a   Cianciaruso, Bruno ^b   Cizmarik, Marta ^c   Germain, Dominique P ^d   Mignani, Renzo ^e   Oliveira, João Paulo ^f   Villalobos, Jacobo ^g   Vujkovac, Bojan ^h   Waldek, Stephen ⁱ   Wanner, Christoph ^j   Warnock, David G ^k  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c GENZYME CORPORATION   (United States)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e Infermi Hospital   (Italy)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^h General Hospital Slovenj Gradec   (Slovenia)

ⁱ SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k University of Alabama at Birmingham   (United States)

more..

Author keywords

Chronic kidney disease; Fabry disease; Genetic renal disease; Kidney transplantation

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; STROKE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALPHA-GALACTOSIDASE; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REGISTRIES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; YOUNG ADULT;

EID: 77649223876     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp554     Document Type: Article

References (24)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease (8th ed). New York NY: McGraw Hill 2001: 3733-3774.
2. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112-128
3. Ortiz A, Oliveira JP, Waldek S, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 1600-1607
4. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebro-vascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-12011
5. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recom-binant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Eng J Med 2001; 345: 9-16
6. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-2749
7. Banikazemi M, Bultas J, Waldek S, et al. Fabry Disease Clinical Trial Study Group: agalsidase-beta therapy for advanced Fabry disease. Ann Intern Med 2007; 146: 77-86
8. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-1557
9. Fervenza FC, Torra R, Warnock DG. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics: Targets and Therapy 2008; 2: 1-22
10. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132-1139
11. Levey AS, Bosch JP. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predictive equation. Ann Int Med 1999; 130: 461-470
12. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987; 34: 571-590
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
14. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the α-ga-lactosidase A gene. Hum Mol Genet 1994; 3: 1795-1799
15. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40
16. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138
17. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000; 69: 2337-2339
18. Mignani R, Feriozzi S, Pisani A, et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008; 23: 1628-1635
19. Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S. Kidney transplant outcomes in patients with Fabry disease. Transplantation 2009; 87: 280-285
20. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249-255 (Pubitemid 34075152)
21. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996; 114-120
22. Go AS, Chertow GM, FanD,McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitaliza-tion. N Engl J Med 2004; 351: 1296-1305
23. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18: 2609-2617
24. Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 2008; 4: 327-336